Molecular Biosystems of San Diego has filed a premarket approvalapplication for FS069, its second-generation ultrasound contrastagent. The submission involved clinical studies for cardiac function,focusing on enhancing endocardial border delineation. In
Molecular Biosystems of San Diego has filed a premarket approvalapplication for FS069, its second-generation ultrasound contrastagent. The submission involved clinical studies for cardiac function,focusing on enhancing endocardial border delineation. In addition,MBI hopes to get approval to use the agent for opacification ofthe left ventricular chamber. MBI has granted Mallinckrodt Medicallicenses to market FS069 in the U.S. and in a number of internationalmarkets (SCAN 12/18/96).
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.